Sheila Buchele, MD in Carl Junction, MO - Anesthesiology

Sheila Buchele, MD is a Anesthesiology physician based in Carl Junction, Missouri. Sheila Buchele is licensed to practice in Missouri (license number 113312) and her current practice location is 113 Forest Dr, Carl Junction, Missouri. She can be reached at her office (for appointments etc.) via phone at (417) 781-2000.

NPI number for Sheila Buchele is 1609869478 and her current mailing address is 113 Forest Dr, Carl Junction, Missouri. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1609869478.

Contact Information

	Sheila Buchele, MD
	113 Forest Dr, Carl Junction, MO 64834-9613
	(417) 781-2000
	Not Available

Physician's Profile

Full Name	Sheila Buchele
Gender	Female
Speciality	Anesthesiology
Location	113 Forest Dr, Carl Junction, Missouri
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1609869478
Provider Enumeration Date: 08/26/2005
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Sheila Buchele such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1609869478	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207L00000X	Anesthesiology	113312 (Missouri)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Sheila Buchele is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Sheila Buchele, MD 113 Forest Dr, Carl Junction, MO 64834-9613 Ph: () -	Sheila Buchele, MD 113 Forest Dr, Carl Junction, MO 64834-9613 Ph: (417) 781-2000

News Archive

Criticism, passion emerge at health care summit

NPR interviewed Rep. Dave Camp, ranking Republican on the House Ways and Means Committee. Camp said: "We were able to at least be heard and have some exposure to the ideas that we've been promoting for a long time. And the president did finally say in the close that we do have ideas that lower costs in insurance and that — do it without increasing taxes. And we don't cut Medicare. And we don't have new mandates in our proposals. So this is really the first opportunity we've had to really focus not only our colleagues and the president, but also the American people on the proposals we've had" (Siegel, 2/25).

Scientists determine protein structure that delivers genetic material of HIV to human cells

A team of scientists at The Scripps Research Institute and the University of Virginia has determined the structure of the protein package that delivers the genetic material of the human immunodeficiency virus to human cells.

PAZ extracts may be useful option for improving plasma cholesterol profile

Health Enhancement Products, Inc., in conjunction with Wayne State University's Department of Nutrition and Food Science in the College of Liberal Arts and Sciences, announces the publication of a scientific article in the Journal of Nutrition & Metabolism, "ProAlgaZyme sub-fraction improves the lipoprotein profile of hypercholesterolemic hamsters, while inhibiting production of betaine, carnitine, and choline metabolites."

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients

Ocera Therapeutics, Inc. presented an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients. The data came from the screening period of the ASTUTE Study, an ongoing Phase 2b study evaluating the safety and efficacy of AST-120 (spherical carbon adsorbent) in the treatment of mild hepatic encephalopathy (MHE). The poster was presented yesterday at the annual meeting of the European Association for the Study of Liver (EASL) in Vienna, Austria. Efficacy and safety data from the ASTUTE study are expected in the summer of 2010.

Sheila Buchele, MD - Anesthesiology in Carl Junction, MO